From the impact of Obamacare to cutting-edge research, biotech buyouts to Big Pharma court battles, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care, and their implications for long-term investors. In this week's edition, the team talks about Novartis' patent dispute, stocks that have both popped and plummeted, and the companies our analysts will be watching in the coming days.
In the following segment, health-care analyst David Williamson discusses two big developments with retail pharmacies that are affecting consumers. Watch and find out why you might be ditching your family doctor for a Walgreen and where you can get the cheapest generic drugs. Fool on!
